Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease
Main finding · Prevalent ASCVDResult — go to the resultAdjusted odds ratio 4.26 95% CI 1.79–10.11Authors' conclusion
MASLD is associated with both an increased prevalence of ASCVD and an increased calculated risk of fatal/nonfatal ASCVD in people with T1D.
Study context
- Population
- Adults with T1D consecutively screened for liver steatosis via abdominal US
- Participants
- 659 adults
- Exposure
- MASLD vs no MASLD
- Outcome
- Prevalence of ASCVD (CAD, PAD or ischaemic stroke) by MASLD status
Methodological detailsconsecutive screening
- Consecutive screening
Main finding
Prevalent ASCVD
Adjusted odds ratio
4.26
95% CI 1.79–10.11
P < 0.001
By group
MASLDvs No MASLD
adjusted OR 4.26 (95% CI 1.79–10.11); P < 0.001
As reported in the abstract
- MASLD prevalence
- 16.8%
- Composite atherosclerotic cardiovascular disease (ASCVD) prevalence difference
- P < 0.001
Observational data: associations, not effects.
Further findings
CAD prevalence
P = 0.031
PAD prevalence
P < 0.001
Ischaemic stroke (CVA) prevalence
P = 0.002
5-year risk of fatal/nonfatal ASCVD (Steno Type 1 Risk Engine) · spread kind not named in abstract
P = 0.034
10-year risk of fatal/nonfatal ASCVD (Steno Type 1 Risk Engine) · spread kind not named in abstract
P = 0.035
Original publication
Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease. Cardiovasc Diabetol. Published 29 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →